Seed Round
$1M target
17% equity
$5M pre-money
Cell-based experiments are a primary component of basic biology research and drug discovery. Currently, cell-based experiments are not reproducible, need to be conducted in large numbers to achieve statistical significance, and as a result are slow, and sometimes impossible, to test hypotheses with. The fundamental reason for this is because the cells used in these experiments are positioned and grown randomly in experimental plates.

TissueX Technologiesmanufactures experimental plates that allow users to conduct the same cell-based experiments with higher precision by controlling the position and growth of cells. As a result, scientists can test hypotheses faster and with increased statistical confidence, leading to efficient filtration of successful drug candidates...
Cell-based experiments are a primary component of basic biology research and drug discovery. Currently, cell-based experiments are not reproducible, need to be conducted in large numbers to achieve statistical significance, and as a result are slow, and sometimes impossible, to test hypotheses with. The fundamental reason for this is because the cells used in these experiments are positioned and grown randomly in experimental plates.

TissueX Technologiesmanufactures experimental plates that allow users to conduct the same cell-based experiments with higher precision by controlling the position and growth of cells. As a result, scientists can test hypotheses faster and with increased statistical confidence, leading to efficient filtration of successful drug candidates
More information

Recommendations

TissueX Technologies comprises a talented team of life science experts mixed with sound technology expertise. They are commercializing unique IP from the University of Toronto and have already gained B2B traction within their domestic market. I am confident that TissueX will build a sustainable business in the life sciences market.

Amazing team with a balanced skill set. UTEST had the privilege to invest in TissueX as part of the 2018 cohort and we couldn't be more satisfied with their progress to date.